Geoffrey Guy
Dr. Geoffrey Guy is the founder and Executive Chairman of GW Pharmaceuticals, a progressive company based in Britain that produces and markets medically useful extracts from cannabis.  Initially intrigued by claims made by multiple sclerosis patients that marijuana eased their symptoms of spasticity, GW has since developed into a highly successful company on the cutting edge of new science.  Dr. Guy received his Diploma of Pharmaceutical Medicine from the Royal Colleges of Physicians in 1984, and is the editor of Medicinal Uses of Cannabis and Cannabinoids.  In 2005, GW achieved an important victory for the medical marijuana movement when their Sativex mouth spray, extracted  from cannabis and used to treat multiple sclerosis, was approved for distribution and sale in Canada.  Dr. Guy has over twenty years of experience in pharmaceutical development covering new chemical entities, biotechnology products, plant-based medicines, controlled drugs and drug delivery systems. He has led over 200 clinical studies including first dose in man, pharmacokinetics, pharmacodynamics and clinical surveys.